Zobrazeno 1 - 10
of 127
pro vyhledávání: '"Donna, Mildvan"'
Autor:
Stephen Furmanek, Bin Cao, Gustavo Lopardo, Eric M. Mortensen, Mark L. Metersky, Francesco Blasi, Julio Ramirez, Francisco Arancibia, Michael S. Niederman, Yann-Erick Claessens, Patrick G. P. Charles, Scott E. Evans, Brandon J. Webb, Elie Azoulay, Takaya Maruyama, Yuichiro Shindo, Martin Witzenrath, Steven D. Burdette, Antoni Torres, Chadi A. Hage, Richard G. Wunderink, Kristina Crothers, Antonio Anzueto, Jean Chastre, Marcos I. Restrepo, Rodrigo Cavallazzi, Charles Feldman, Mathias W. Pletz, Donna Mildvan, Jordi Rello, Muriel Fartoukh, Carlos M. Luna, Stefano Aliberti, Forest W Arnold, James D. Chalmers, Daniel M. Musher, Thomas M. File, Charles S. Dela Cruz, Filipe Froes, Tobias Welte, Rosario Menéndez, Jose Bordon, Grant W. Waterer, Martin Gnoni, Xavier Duval, Nathan C. Dean
Publikováno v:
Chest. 158:1896-1911
Background Community-acquired pneumonia (CAP) guidelines have improved the treatment and outcomes of patients with CAP, primarily by standardization of initial empirical therapy. But current society-published guidelines exclude immunocompromised pati
Publikováno v:
Journal of the International Association of Providers of AIDS Care, Vol 12 (2013)
Background: Pegylated interferon (PEG-IFN)/ribavirin (RBV)-related cytopenias have been associated with improved virological outcomes among hepatitis C virus (HCV)-monoinfected patients. This analysis evaluated PEG-IFN/RBV-related cytopenias with vir
Externí odkaz:
https://doaj.org/article/9a5d01ca4f664263888dcdcb893402b0
Publikováno v:
Open Forum Infectious Diseases
Background Antibiotic treatment failure is common among patients with community-acquired pneumonia (CAP) who are managed in the outpatient setting and is associated with higher mortality and increased health care costs. This study’s objectives were
Autor:
Cindy J. Bednasz, Charles S. Venuto, Qing Ma, Eric S. Daar, Paul E. Sax, Margaret A. Fischl, Ann C. Collier, Kimberly Y. Smith, Camlin Tierney, Edward P. Acosta, Donald E. Mager, Gene D. Morse, Hector H. Bolivar, Sandra Navarro, Susan L. Koletar, Diane Gochnour, Edward Seefried, Julie Hoffman, Judith Feinberg, Michelle Saemann, Kristine Patterson, Donna Pittard, David Currin, Kerry Upton, Michael Saag, Graham Ray, Steven Johnson, Bartolo Santos, Connie A. Funk, Michael Morgan, Brenda Jackson, Pablo Tebas, Aleshia Thomas, Ge-Youl Kim, Michael K. Klebert, Jorge L. Santana, Santiago Marrero, Jane Norris, Sandra Valle, Gary Matthew Cox, Martha Silberman, Sadia Shaik, Ruben Lopez, Margie Vasquez, Demetre Daskalakis, Christina Megill, Todd Stroberg, Jessica Shore, Babafemi Taiwo, Mitchell Goldman, Molly Boston, Jeffrey Lennox, Carlos del Rio, Timothy W. Lane, Kim Epperson, Annie Luetkemeyer, Mary Payne, Barbara Gripshover, Dawn Antosh, Jane Reid, Mary Adams, Sheryl S. Storey, Shelia B. Dunaway, Joel Gallant, Ilene Wiggins, Joan A. Swiatek, Joseph Timpone, Princy Kumar, Ardis Moe, Maria Palmer, Jon Gothing, Joanne Delaney, Kim Whitely, Ann Marie Anderson, Scott M. Hammer, Michael T. Yin, Mamta Jain, Tianna Petersen, Roberto Corales, Christine Hurley, Keith Henry, Bette Bordenave, Amanda Youmans, Mary Albrecht, Richard B. Pollard, Abimbola Olusanya, Paul R. Skolnik, Betsy Adams, Karen T. Tashima, Helen Patterson, Michelle Ukwu, Lauren Rogers, Henry H. Balfour, Kathy A. Fox, Susan Swindells, Frances Van Meter, Gregory Robbins, Nicole Burgett-Yandow, Charles E. Davis, Colleen Boyce, William A. O’Brien, Gerianne Casey, Chiu-Bin Hsaio, Jeffrey L. Meier, Jack T. Stapleton, Donna Mildvan, Manuel Revuelta, Wafaa El Sadr, Avelino Loquere, Nyef El-Daher, Tina Johnson, Robert Gross, Kathyrn Maffei, Valery Hughes, Glenn Sturge, Deborah McMahon, Barbara Rutecki, Michael Wulfsohn, Andrew Cheng, Norbert Bischofberger, Lynn Dix, Qiming Liao
Publikováno v:
Antimicrobial Agents and Chemotherapy. 63
AIDS Clinical Trial Group study A5202 (ClinicalTrials.gov identifier {"type":"clinical-trial","attrs":{"text":"NCT00118898","term_id":"NCT00118898"}}NCT00118898) was a phase 3b, randomized, partially blinded equivalence study of open-label atazanavir
Autor:
Marya Gwadz, M. Riedel, A. S. Ritchie, G. Arredondo, A. Banfield, Noelle R. Leonard, Donna Mildvan, C. M. Cleland
Publikováno v:
Health Education Research. 28:574-590
AIDS clinical trials (ACTs) are critical to the development of new treatments for HIV infection. However, people of color living with HIV/AIDS are involved in ACTs at disproportionally low rates, with African-Americans experiencing the greatest under
Autor:
Robert W. Coombs, Susan Cu-Uvin, Susan H. Eshleman, Irving F. Hoffman, Jonathan Uy, Donna Mildvan, David W. Haas, Thomas B. Campbell, Kelly Burke, David D. Celentano, Edith Swann, Ronald T. Mitsuyasu, Ann C. Collier, Beatriz Grinsztejn, Newton Kumwenda, Laurie Frarey, Breno Santos, Apsara Nair, Ann Walawander, David Chilongozi, Bartolo Santos, Taha E. Taha, Chiedza Maponga, Sima Berendes, S. Poongulali, M. P. Revuelta, Charles van der Horst, Robert C. Bollinger, Suniti Solomon, Jorge Sanchez, Francis Martinson, N. Kumarasamy, Joan Dragavon, James Hakim, Rosa Infante, Richard B. Pendame, Farida Amod, Roy M. Gulick, Jody Lawrence, P. Jan Geiseler, Joan Gormley, Judith S. Currier, Cynthia Firnhaber, Laura Moran, Larisa Zifchak, Myron S. Cohen, Keith A. Pappa, Beverly Putnam, Charles Flexner, David H. Haas, Sandra W. Cardoso, Karin L. Klingman, Ruben Lopez, Joel E. Gallant, James F. Rooney, Jabin Sharma, Edde Loeliger, Pablo Tebas, Beverly E. Sha, Barbara Brizz, Wendy Snowden, Scott M. Hammer, Johnstone Kumwenda, Javier R. Lama, Karin Nielsen, Christine Wanke, Steve Tabet, Alberto La Rosa, Wadzanai Samaneka, Joseph J. Eron, Michael K. Klebert, Renard S. Descallar, Bharat Ramratnam, Kenneth H. Mayer, Cheryl Marcus, Yvonne J. Bryson, Nikki Gettinger, Vicki L. Bailey, Adriana Andrade, David Shugarts, Robert T. Schooley, Ken Braun, David Currin, Eric S. Daar, Michael Hughes, Laura M. Smeaton, Vladimir Berthaud, Sharlaa Badal-Faesen, Victor De Gruttola, Cecelia Kanyama, Timothy P. Flanigan, Mark A. Winters, Yvette Delph, Smanga Ntshele, Peter N. Kazembe, Deise Lucia Faria, Mina C. Hosseinipour, Steven A. Safren, Ronald L. Barnett, Ana Martinez, Abel Tilahun Eshete, Beth D. Mullan, Henry H. Balfour, Ge-Youl Kim, Anthony Chisada, Yajing Bao, Ian Sanne, Virginia Kayoyo, Susan A. Fiscus, Janice M. Fritsche, Nancy Webb
Publikováno v:
Clinical Infectious Diseases. 57:290-297
Background. Combination antiretroviral therapy (cART) reduces genital tract human immunodeficiency virus type 1 (HIV-1) load and reduces the risk of sexual transmission, but little is known about the efficacy of cART for decreasing genital tract vira
Autor:
Jayvant Heera, Daniel Podzamczer, Anthony Mills, Simon Portsmouth, Donna Mildvan, Manoli Vourvahis, Charles Craig, Hernan Valdez, Manuel Leal, Srinivas Rao Valluri, Alex R. Rinehart, Soe Than, Gerd Fätkenheuer, Lynn McFadyen
Publikováno v:
JAIDS Journal of Acquired Immune Deficiency Syndromes. 62:164-170
This study was performed to evaluate a once-daily dual-therapy regimen, maraviroc (MVC) + atazanavir/ritonavir (ATV/r), in treatment-naive patients.A phase 2b, randomized, open-label pilot study.In Study A4001078 (NCT00827112), treatment-naive patien
Publikováno v:
Open Forum Infectious Diseases. 3
Autor:
Charles M. Cleland, Amanda S. Ritchie, Donna Mildvan, Noelle R. Leonard, Pablo Colon, Angela Banfield, Marion Riedel, Marya Gwadz
Publikováno v:
AIDS and Behavior. 17:801-812
African-American and Latino/Hispanic persons living with HIV/AIDS are underrepresented in AIDS clinical trials (ACTs). The aim of this paper was to uncover factors, either unmodifiable or not directly targeted for change, that predicted screening for
Autor:
Charles M. Cleland, Marion Riedel, Donna Mildvan, Marya Gwadz, Noelle R. Leonard, Angela Banfield
Publikováno v:
American Journal of Public Health. 101:1096-1102
Objectives. We examined the efficacy of a peer-driven intervention to increase rates of screening for AIDS clinical trials among African Americans and Hispanics living with HIV/AIDS. Methods. We used a randomized controlled trial design to examine th